长链非编码RNA AFAP1-AS1在癌症中作用及其机制的研究进展

癌症一直是全球非感染性疾病死亡的主要原因之一,癌症的有效筛查和早期诊断、早期治疗一直以来是临床的一大难点,鉴定新的生物标志物或分子靶标以改善癌症患者的诊断和治疗刻不容缓.近年来研究发现,长链非编码RNA(long non-coding RNA,lncRNA)是一系列生物行为和包括肿瘤在内的疾病发生、发展的主要调节因子,...

Research progress on the mechanism of long chain non-coding RNA AFAP1-AS1 in cancer

Cancer is one of the leading causes of death from non-infectious diseases in the whole world. Moreover, effective screening and early diagnosis and treatment of cancers have always been a major clinical difficulty. Therefore, it is urgent that novel potential biomarkers or molecular targets are identified to improve the diagnosis and treatment of cancer patients. In recent years, it has been found that long non-coding RNAs (lncRNAs) are a series of main regulatory factors in biological behaviors and diseases including tumors, and are expected to become novel biomarkers and molecular targets for tumor detection and treatment. Actin filament-associated protein 1-antisense RNA 1 (AFAP1-AS1) was initially identified as a carcinogenic lncRNA in esophageal adenocarcinoma, and later as a carcinogenic regulator of various malignant tumors. The abnormal overexpression of AFAP1-AS1 can regulate the proliferation, apoptosis, invasion and metastasis of tumor cells through different molecular mechanisms. The up- regulation of AFAP1-AS1 in tumor tissues has important clinical significance. Understanding the function and mechanism of this lncRNA in cancers can further help to explore new strategies for the prevention and treatment of malignant tumors. Therefore, this paper reviewed the effects, relevant molecular mechanisms and potential clinical significance of AFAP1-AS1 in multiple human malignant tumors, so as to provide a scientific theoretical basis for its early clinical application.